Anixa Biosciences Inc

NASDAQ ANIX

Data sourced from

and

Download Data

Anixa Biosciences Inc Free Cash Flow to Equity (FCFE) 3 year CAGR for the Trailing 12 Months (TTM) ending September 19, 2024

Anixa Biosciences Inc Free Cash Flow to Equity (FCFE) 3 year CAGR is NA for the Trailing 12 Months (TTM) ending September 19, 2024. Free Cash Flow to Equity represents the cash flow available to equity shareholders after accounting for capital expenditures and net acquisitions. It indicates the amount of cash flow that can be distributed to shareholders or reinvested in the business. It is useful in assessing the company's ability to generate cash flow for its equity investors. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

NASDAQ: ANIX

Anixa Biosciences Inc

CEO	Dr. Amit Kumar Ph.D.
IPO Date	Jan. 1, 1987
Location	United States
Headquarters	3150 Almaden Expressway, San Jose, CA, United States, 95118
Employees	4
Sector	Healthcare
Industry	Biotechnology

Description

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Key trends